报价延迟最少15分钟:2026/09/03 20:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.79 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.29/-1.02
|
|
企业价值
919.33M
|
| 资产负债 |
|
每股账面净值
0.62
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
559.00K
|
|
每股收益
0.58
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs. |
